VICTORIA, British Columbia--(BUSINESS WIRE)--$IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is thrilled to announce that its subs
CHICAGO--(BUSINESS WIRE)--An oral presentation at the American Heart Association’s Scientific Sessions examined recent reporting rates of esophageal injury after left atrial ablation for the treatment of atrial fibrillation and found that the rates have
VANCOUVER, British Columbia--(BUSINESS WIRE)--Ondine Biomedical’s Steriwave nasal photodisinfection technology has been shortlisted in the biomedical category of the 2024 international society for optics and photonics SPIE Prism Awards. Ondine’s nasal
EVM-301 Series Presented and published leading scientific research describing development and screening methods for non-hallucinogenic, neuroplastogenic drug candidates in Enveric’s EVM301 Series of candidates targeting the treatment of mental health
FDA approves ATI-1501 for Metronidazole Oral Suspension 500mg/5mL and its brand name LIKMEZ™ Appili received an additional funding commitment from the U.S. Air Force Academy for ATI-1701, bringing the total program funding awarded to US$14 million Appi
PHILADELPHIA--(BUSINESS WIRE)--Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced two poster presentations at the 2023 Society for NeuroOncology (SNO) 28th Annual Meeting in Va
PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics today announced an oral presentation highlighting updated Phase 1/2a clinical data for plixorafenib (FORE8394; PLX8394), the company’s novel, investigational, small-molecule, next-generation, orally av
ROOT, Switzerland--(BUSINESS WIRE)--$NVCR--Novocure (NASDAQ: NVCR) today announced that research on Tumor Treating Fields (TTFields) therapy, including new data from the phase 2 2-THE-TOP trial and real-world evidence from patients diagnosed with glioblas
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic
Presented positive initial data from ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, including an overall RECIST response rate of 50% in patients with heavily pre-treated gynecological tumors Repare
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.